Theme 4 : "Marine biological resources/biotechnology"
Declared a ‘matter of national concern’ in 2007, Alzheimer’s disease affects almost one million people in France. Given the ageing population, this figure is increasing at a rate of more than 200 000 new cases per year. It is no surprise that the social and economic impact of this disease is becoming a cause of particular concern. Moreover, the causes and mechanisms of this disease are still not understood and there is currently no form of preventative treatment or cure.
The CNRS laboratory run by Dr. Laurent Meijer from the Station Biologique de Roscoff (biological research station) has identified and characterised several families of molecules of marine origin, notably extracted from sponges, which have interesting properties for the treatment of certain human pathologies, including neurodegenerative conditions such as Alzheimer’s disease.
The PHARMASEA project brings together two companies, ManRos Therapeutics and C.RIS Pharma, and four research centres, including the CNRS. Its aim is to characterise several families of molecules of interest to the project in the treatment of Alzheimer’s disease. In particular, the PHARMASEA partners are interested in the kinase-inhibitor properties of these molecules. Kinases are enzymes essential for cellular metabolism and some are implicated in Alzheimer’s disease. Over the last few years, kinase inhibitors have become one of the most promising avenues for research and development of innovative drugs in numerous therapeutic fields. This ambitious project will on the one hand validate candidate drugs by carrying out pre-clinical trials on a new family of compounds for the treatment of Alzheimer’s disease, and on the other hand develop new cellular models for studying this pathology in vitro and in vivo. In particular, the project incorporates all the statutory pharmacological and pre-clinical studies required for drawing up a human clinical trials application dossier.
PHARMASEA project partners
Companies
Research centres
-
CNRS, DR17, Nantes.
-
University of Rennes 1: The “Chemical engineering and molecules for the living” group under Prof. Jean-Pierre Bazureau specialises in ‘green chemistry’.
-
Paris Descartes University: Research team of Prof. Hervé Galons specialises in the synthesis of new organic molecules.
-
Saclay CEA, iBiTec-S: The “Drugs and Neuropharmacology” group in the Pharmacology and Immunoanalysis department is directed by Dr Aloïse Mambondzo.
-
Inserm, Paris
Contact :
-
Cette adresse email est protégée contre les robots des spammeurs, vous devez activer Javascript pour la voir.
|
